The Urovysion® F.I.S.H. test compared to standard cytology for surveillance of non-muscle invasive bladder cancer

Massimo Maffezzini, Giacomo Capponi, Stefania Casazza, Fabio Campodonico, Roberto Bandelloni, Matteo Puntoni

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the potential contribution of urinary fluorescent in situ hybridization in the prediction of the risk of recurrence and progression of men undergoing follow-up for NMIBC Materials and Methods: Patients with a history of NMIBC being followed with urinary cytology and cystoscopy were included in the study. Patients with Carcinoma in situ or tumour stage higher than pT1 were excluded from this analysis. F.l.S.H. Test consisted in the Urovysion kit, able to detect four chromosomal abnormalities, specifically, 9p21, Ch 3, 7 and 17. Results: Of a total of 133 evaluable patients that constitute the subject of the present report 87 patients had a positive urinary F.l.S.H. At a median follow up time of 36 mos 58 patients underent recurrence (43.6%). In this group 42 (72.6%) and 27 (46.6%) patients had a positive F.l.S.H. and UC, respectively (p = 0.005). A total of 17 patients (12.8%) underwent progression of stage or grade; of those with a positive F.l.S.H. Test and positive UC were 14 (82.4%) and 8 (47.1 %), respectively (p = 0.049). Conclusion: In patients with history of NMIBC, F.l.S.H. showed a statistically significantly greater capability that UC in identifying patients with recurrence and progression of disease.

Original languageEnglish
Pages (from-to)127-131
Number of pages5
JournalArchivio Italiano di Urologia e Andrologia
Volume80
Issue number4
Publication statusPublished - Dec 2008

Keywords

  • Fluorescence in situ hybridization
  • Non-muscle invasive bladder cancer
  • Progression
  • Recurrence
  • Urinary cytology

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'The Urovysion® F.I.S.H. test compared to standard cytology for surveillance of non-muscle invasive bladder cancer'. Together they form a unique fingerprint.

  • Cite this

    Maffezzini, M., Capponi, G., Casazza, S., Campodonico, F., Bandelloni, R., & Puntoni, M. (2008). The Urovysion® F.I.S.H. test compared to standard cytology for surveillance of non-muscle invasive bladder cancer. Archivio Italiano di Urologia e Andrologia, 80(4), 127-131.